NCT02564744

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Debiopharm International SA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.

Conditions

• Diffuse Large B-Cell Lymphoma
• B-cell Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	Debio 1562	Administered as IV Infusion.
DRUG	Rituximab	Administered as IV Infusion.

Timeline

• Start date: 2016-06-05
• Primary completion: 2021-01-13
• Completion: 2021-06-25
• First posted: 2015-10-01
• Last updated: 2024-06-12
• Results posted: 2024-05-17

Locations

39 sites across 9 countries: United States, Belgium, Bulgaria, Czechia, Hungary, Italy, Poland, Switzerland, Ukraine

Regulatory

• FDA-regulated drug study